Literature DB >> 27826681

Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.

Federico Pessina1, Pierina Navarria2, Luca Cozzi3,4, Stefano Tomatis2, Marco Riva1, Anna Maria Ascolese2, Armando Santoro5,6, Matteo Simonelli5, Lorenzo Bello1, Marta Scorsetti2,6.   

Abstract

The role of surgical resection in progressive or recurrent glioblastoma multiforme (GBM) lack of high level of evidence. The aim of this evaluation was to assess the role of surgical resection in relapsing GBM, in relation to the extent of surgical resection (EOR) and the amount of residual tumor volume (RTV). Among patients treated for newly diagnosed GBM between September 2008-December 2014, 64 patients with recurrent GBM were included in this retrospective evaluation. All patients underwent surgical resection followed by adjuvant treatments, chemotherapy and/or radiotherapy Results were evaluated in terms of local control (LC) rate, progression free survival (PFS) and patients overall survival (OS). Gross total resection (GTR) (>90%) was achieved in 48 (75%) patients and subtotal resection (STR) in 16 (25%). RTV was 0 in 40 (62.5%) patients and >0 in 24 (37.5%). No severe postoperative morbidity occurred. The median LC time was 6.0 ± 0.1 months (95% CI 5.29-8.55), with a 1 and 2 years LC rate of 29.4 ± 6.9%. The median PFS time was 6.8 ± 0.8 months, with a 1 year PFS rate of 27.2 ± 7.2% (95% CI 14.2-41.9). The median OS time was 10.3 ± 0.5 months (95% CI 7.6-10.4) with a 1 and 2 years OS rate of 22.5 ± 6.7% (95% CI 10.9-36.6). On univariate analysis EOR and RTV were recorded as conditioning LC and survival. These data was confirmed also in multivariate analysis only for RTV (p < 0.01). Recurrent GBM can take advantage of repeated surgery in selected patients with younger age and good clinical status. The entity of surgical resection was confirmed as conditioning survival.

Entities:  

Keywords:  Prognostic factors; Recurrent glioblastoma multiforme; Surgical resection

Mesh:

Year:  2016        PMID: 27826681     DOI: 10.1007/s11060-016-2310-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.

Authors:  Ellen S Mandl; C M F Dirven; D R Buis; T J Postma; W P Vandertop
Journal:  Surg Neurol       Date:  2008-02-08

Review 2.  'Recurrent' glioblastoma multiforme, when should we reoperate?

Authors:  Giuseppe M V Barbagallo; Michael D Jenkinson; Andrew R Brodbelt
Journal:  Br J Neurosurg       Date:  2008-06       Impact factor: 1.596

3.  Radical surgery and reoperation in supratentorial malignant glial tumors.

Authors:  M Daneyemez; F Gezen; Z Canakçi; S Kahraman
Journal:  Minim Invasive Neurosurg       Date:  1998-12

4.  Survival and functional status after resection of recurrent glioblastoma multiforme.

Authors:  F G Barker; S M Chang; P H Gutin; M K Malec; M W McDermott; M D Prados; C B Wilson
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

5.  An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.

Authors:  Mark E Oppenlander; Andrew B Wolf; Laura A Snyder; Robert Bina; Jeffrey R Wilson; Stephen W Coons; Lynn S Ashby; David Brachman; Peter Nakaji; Randall W Porter; Kris A Smith; Robert F Spetzler; Nader Sanai
Journal:  J Neurosurg       Date:  2014-01-31       Impact factor: 5.115

6.  Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis.

Authors:  Akash J Patel; Dima Suki; Mustafa Aziz Hatiboglu; Vikas Y Rao; Benjamin D Fox; Raymond Sawaya
Journal:  J Neurosurg       Date:  2015-03-20       Impact factor: 5.115

7.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

Review 10.  New (alternative) temozolomide regimens for the treatment of glioma.

Authors:  Wolfgang Wick; Michael Platten; Michael Weller
Journal:  Neuro Oncol       Date:  2008-09-04       Impact factor: 12.300

View more
  3 in total

1.  Second surgery for progressive glioblastoma: a multi-centre questionnaire and cohort-based review of clinical decision-making and patient outcomes in current practice.

Authors:  P M Brennan; R Borchert; C Coulter; G R Critchley; B Hall; D Holliman; I Phang; S J Jefferies; S Keni; L Lee; I Liaquat; H J Marcus; S Thomson; L Thorne; M Vintu; A N Wiggins; M D Jenkinson; S Erridge
Journal:  J Neurooncol       Date:  2021-03-31       Impact factor: 4.130

2.  Impact on Radiation Dose and Volume V57 Gy of the Brain on Recurrence and Survival of Patients with Glioblastoma Multiformae.

Authors:  Igor Stojkovski; Valentina Krstevska; Snezhana Smichkoska
Journal:  Radiol Oncol       Date:  2017-11-01       Impact factor: 2.991

3.  Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?

Authors:  Melanie Barz; Stefanie Bette; Insa Janssen; A Kaywan Aftahy; Thomas Huber; Friederike Liesche-Starnecker; Yu-Mi Ryang; Benedikt Wiestler; Stephanie E Combs; Bernhard Meyer; Jens Gempt
Journal:  BMC Neurol       Date:  2022-01-21       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.